Featured Content

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being ...

Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.

BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.

More Features>>>

Breast Cancer Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs